Cannabinoid receptor 2 (CB) is a promising therapeutic target for immunological modulation. There is, however, a deficit of knowledge regarding CB signaling and function in human primary immunocompetent cells. We applied an experimental paradigm which closely models the state of human primary leukocytes (PBMC; peripheral blood mononuclear cells) to characterize activation of a number of signaling pathways in response to a CB-selective ligand (HU308).
View Article and Find Full Text PDFArrestin translocation and signaling have come to the fore of the G protein-coupled receptor molecular pharmacology field. Some receptor-arrestin interactions are relatively well understood and considered responsible for specific therapeutic or adverse outcomes. Coupling of arrestins with cannabinoid receptors 1 (CB) and 2 (CB) has been reported, though the majority of studies have not systematically characterized the differential ligand dependence of this activity.
View Article and Find Full Text PDFCannabinoid receptor 2 (CB) is predominantly distributed in immune tissues and cells and is a promising therapeutic target for modulating inflammation. In this study we designed and synthesised a series of 2,4,6-trisubstituted 1,3,5-triazines with piperazinylalkyl or 1,2-diethoxyethane (PEG2) chains as CB agonists, all of which were predicted to be considerably more polar than typical cannabinoid ligands. In this series, we found that triazines containing an adamantanyl group were conducive to CB binding whereas those with a cyclopentyl group were not.
View Article and Find Full Text PDFG protein-coupled receptors (GPCRs) are important therapeutic targets and therefore extensively studied. Like most transmembrane proteins, there has been considerable difficulty in developing reliable specific antibodies for them. To overcome this, epitope tags are often used to facilitate antibody recognition in studies on fundamental receptor signalling and trafficking.
View Article and Find Full Text PDF